Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $344.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 4.16% year-over-year to $344.9 million; the TTM figure through Mar 2026 stood at $344.9 million (up 4.16% YoY), while the FY2025 annual figure was $345.0 million, up 3.55% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $344.9 million, roughly flat from $345.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $345.0 million in Q4 2025, with the low at $2000.0 in Q3 2024.
• The 5-year median for Total Non-Current Liabilities is $1.1 million (2023), against an average of $119.9 million.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 99.77% in 2024, then jumped 16108650.0% in 2025.
• Syndax Pharmaceuticals' Total Non-Current Liabilities stood at $722000.0 in 2022, then decreased by 18.56% to $588000.0 in 2023, then soared by 56556.97% to $333.1 million in 2024, then gained by 3.55% to $345.0 million in 2025, then decreased by 0.03% to $344.9 million in 2026.
• Business Quant data shows SNDX's Total Non-Current Liabilities at $344.9 million in Q1 2026, $345.0 million in Q4 2025, and $322.2 million in Q3 2025.